Published in J Infect Dis on July 01, 1998
Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis (2009) 6.17
Joint modelling of paired sparse functional data using principal components. Biometrika (2008) 3.37
Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev (2001) 2.87
Initial increase in blood CD4(+) lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest (1999) 2.48
High-level HIV-1 viremia suppresses viral antigen-specific CD4(+) T cell proliferation. Proc Natl Acad Sci U S A (2001) 2.32
HIV-1 antiretroviral drug therapy. Cold Spring Harb Perspect Med (2012) 2.18
Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol (2013) 2.01
Preservation of lymphocyte immunophenotype and proliferative responses in cryopreserved peripheral blood mononuclear cells from human immunodeficiency virus type 1-infected donors: implications for multicenter clinical trials. The ACTG Immunology Advanced Technology Laboratories. Clin Diagn Lab Immunol (2000) 1.88
Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis (2011) 1.82
Role for HLA class II molecules in HIV-1 suppression and cellular immunity following antiretroviral treatment. J Clin Invest (2001) 1.72
Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol (2000) 1.67
Identification and antigenicity of broadly cross-reactive and conserved human immunodeficiency virus type 1-derived helper T-lymphocyte epitopes. J Virol (2001) 1.62
Efficient Hybrid EM for Linear and Nonlinear Mixed Effects Models with Censored Response. Comput Stat Data Anal (2007) 1.37
Correlates of immune activation marker changes in human immunodeficiency virus (HIV)-seropositive and high-risk HIV-seronegative women who use illicit drugs. J Infect Dis (2003) 1.33
A randomized therapeutic vaccine trial of canarypox-HIV-pulsed dendritic cells vs. canarypox-HIV alone in HIV-1-infected patients on antiretroviral therapy. Vaccine (2009) 1.21
Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol (2005) 1.06
Interferon-alpha administration enhances CD8+ T cell activation in HIV infection. PLoS One (2012) 1.06
HIV pathogenesis: the host. Cold Spring Harb Perspect Med (2012) 1.02
Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine. PLoS One (2013) 1.01
The lymph node in HIV pathogenesis. Semin Immunol (2008) 0.94
Antiretroviral therapy: current drugs. Infect Dis Clin North Am (2014) 0.94
Modelling human immunodeficiency virus ribonucleic acid levels with finite mixtures for censored longitudinal data. J R Stat Soc Ser C Appl Stat (2012) 0.93
HIV-1-specific CD4+ T cell responses in chronically HIV-1 infected blippers on antiretroviral therapy in relation to viral replication following treatment interruption. J Clin Immunol (2006) 0.92
HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol (2012) 0.92
Modulation of human immunodeficiency virus (HIV)-specific immune response by using efavirenz, nelfinavir, and stavudine in a rescue therapy regimen for HIV-infected, drug-experienced patients. Clin Diagn Lab Immunol (2002) 0.91
Insights into pathogenic events of HIV-associated Kaposi sarcoma and immune reconstitution syndrome related Kaposi sarcoma. Infect Agent Cancer (2008) 0.90
Reconstitution of human thymic implants is limited by human immunodeficiency virus breakthrough during antiretroviral therapy. J Virol (1999) 0.90
Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115. AIDS Res Hum Retroviruses (2009) 0.90
Immunological changes in peripheral blood and in lymphoid tissue after treatment of HIV-infected subjects with highly active anti-retroviral therapy (HAART) or HAART + IL-2. Clin Exp Immunol (1999) 0.89
Antiviral therapy reduces viral burden but does not prevent thymic involution in young cats infected with feline immunodeficiency virus. Antimicrob Agents Chemother (2000) 0.89
Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sex Transm Infect (1999) 0.87
Immunity in HIV-1-infected adults with a previous state of moderate-severe immune-suppression and more than 500 CD4+ T cell after highly active antiretroviral therapy. J Clin Immunol (2004) 0.86
Suboptimal immune reconstitution in vertically HIV infected children: a view on how HIV replication and timing of HAART initiation can impact on T and B-cell compartment. Clin Dev Immunol (2012) 0.86
A double-blind, adjuvant-controlled trial of human immunodeficiency virus type 1 (HIV-1) immunogen (Remune) monotherapy in asymptomatic, HIV-1-infected thai subjects with CD4-cell counts of >300. Clin Diagn Lab Immunol (2000) 0.85
Replication capacity in relation to immunologic and virologic outcomes in HIV-1-infected treatment-naive subjects. J Acquir Immune Defic Syndr (2009) 0.85
Lymphoid fibrosis occurs in long-term nonprogressors and persists with antiretroviral therapy but may be reversible with curative interventions. J Infect Dis (2014) 0.84
Empirical Likelihood Based Inferences for Partially Linear Models with Missing Covariates. Aust N Z J Stat (2008) 0.84
Entrapment of recent thymic emigrants in lymphoid tissues from HIV-infected patients: association with HIV cellular viral load. AIDS (2002) 0.83
Programmed death 1 receptor changes ex vivo in HIV-infected adults following initiation of highly active antiretroviral therapy. Clin Vaccine Immunol (2012) 0.83
The pathogenesis of HIV infection: stupid may not be so dumb after all. Retrovirology (2006) 0.83
Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. AIDS Res Hum Retroviruses (2010) 0.82
Hospitalization risk following initiation of highly active antiretroviral therapy. HIV Med (2009) 0.82
Lymphoma immune reconstitution inflammatory syndrome in the center for AIDS research network of integrated clinical systems cohort. Clin Infect Dis (2014) 0.81
In vitro hydroxyurea decreases Th1 cell-mediated immunity. Clin Diagn Lab Immunol (2001) 0.81
Delayed reconstitution of B cell immunity to pneumococcus in HIV-infected Malawian children on antiretroviral therapy. J Infect (2014) 0.79
HIV patients treated with low-dose prednisolone exhibit lower immune activation than untreated patients. BMC Infect Dis (2012) 0.78
Semiparametric variance components models for genetic studies with longitudinal phenotypes. Biostatistics (2011) 0.78
T-helper-cell proliferative responses to whole-killed human immunodeficiency virus type 1 (HIV-1) and p24 antigens of different clades in HIV-1-infected subjects vaccinated with HIV-1 immunogen (Remune). Clin Diagn Lab Immunol (2000) 0.78
T Cell Activation and Cytokine Profile of Tuberculosis and HIV-Positive Individuals during Antituberculous Treatment and Efavirenz-Based Regimens. PLoS One (2013) 0.78
The Role of Antigen-presenting Cells in HIV Pathogenesis. Curr Infect Dis Rep (2002) 0.78
Longitudinal functional principal component modeling via Stochastic Approximation Monte Carlo. Can J Stat (2010) 0.77
Interleukin-15 production by monocyte-derived dendritic cells and T cell proliferation in HIV-infected patients with discordant response to highly active antiretroviral therapy. Clin Exp Immunol (2004) 0.77
Transient expansion of activated CD8(+) T cells characterizes tuberculosis-associated immune reconstitution inflammatory syndrome in patients with HIV: a case control study. J Inflamm (Lond) (2013) 0.77
Augmented HIV-specific interferon-gamma responses, but impaired lymphoproliferation during interruption of antiretroviral treatment initiated in primary HIV infection. J Acquir Immune Defic Syndr (2011) 0.76
SIV antigen immunization induces transient antigen-specific T cell responses and selectively activates viral replication in draining lymph nodes in retroviral suppressed rhesus macaques. Retrovirology (2011) 0.76
Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients. MBio (2016) 0.76
Segmental modeling of changing viral load to assess drug resistance in HIV infection. Stat Methods Med Res (2007) 0.75
A 33-year-old patient with human immunodeficiency virus on antiretroviral therapy with efavirenz-induced complex partial seizures: a case report. J Med Case Rep (2016) 0.75
Parametrically guided estimation in nonparametric varying coefficient models with quasi-likelihood. J Nonparametr Stat (2015) 0.75
Immune recovery uveitis in HIV patients with cytomegalovirus retinitis in the era of HAART therapy-a 5-year study from Singapore. J Ophthalmic Inflamm Infect (2016) 0.75
HIV DYNAMICS AND NATURAL HISTORY STUDIES: JOINT MODELING WITH DOUBLY INTERVAL-CENSORED EVENT TIME AND INFREQUENT LONGITUDINAL DATA. Ann Appl Stat (2011) 0.75
Characteristics of hepatitis C virus infection in HIV-infected people. Can J Infect Dis (2001) 0.75
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Stromal gene signatures in large-B-cell lymphomas. N Engl J Med (2008) 11.34
Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel. JAMA (2000) 7.81
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science (1991) 7.16
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Determinants of HIV-1 shedding in the genital tract of women. Lancet (2001) 5.10
Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med (1998) 5.08
Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 4.96
HIV viral load markers in clinical practice. Nat Med (1996) 4.78
Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. JAMA (1998) 4.42
Interleukin-2 therapy in patients with HIV infection. N Engl J Med (2009) 4.38
Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet (1993) 4.06
Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med (1995) 3.86
Evidence for the effects of a superantigen in rheumatoid arthritis. Science (1991) 3.71
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine. Antimicrob Agents Chemother (1992) 3.52
Mapping of contralateral space in retinotopic coordinates by a parietal cortical area in humans. Science (2001) 3.41
An association between viral genes and human oncogenic alterations: the adenovirus E1A induces the Ewing tumor fusion transcript EWS-FLI1. Nat Med (1999) 3.27
Evidence for an interferon-inducible gene, Ifi202, in the susceptibility to systemic lupus. Immunity (2001) 3.18
Autoimmune disease: why and where it occurs. Nat Med (2001) 3.04
A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med (1995) 3.04
Noninvasive imaging of alpha(v)beta3 integrin expression using 18F-labeled RGD-containing glycopeptide and positron emission tomography. Cancer Res (2001) 3.01
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med (1995) 2.88
Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA (1999) 2.82
Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature. Clin Infect Dis (2001) 2.80
Premutation and intermediate-size FMR1 alleles in 10572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet (2002) 2.77
N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem (1999) 2.76
Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults. AIDS (2001) 2.75
Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma. Am J Surg Pathol (1982) 2.73
Primary structure of elongation factor Tu from Escherichia coli. Proc Natl Acad Sci U S A (1980) 2.72
Vancomycin-resistant gram-positive bacteria isolated from human sources. J Clin Microbiol (1988) 2.71
Selective expansion of T cells expressing V beta 2 in toxic shock syndrome. J Exp Med (1990) 2.71
Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrob Agents Chemother (1998) 2.67
Productive infection of T cells in lymphoid tissues during primary and early human immunodeficiency virus infection. J Infect Dis (2001) 2.63
Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrob Agents Chemother (1997) 2.57
Selective expansion of T cells expressing T-cell receptor variable regions V beta 2 and V beta 8 in Kawasaki disease. Proc Natl Acad Sci U S A (1992) 2.56
Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med (1997) 2.55
Phase 2b, randomized, double-blind 12-week studies of TZP-102, a ghrelin receptor agonist for diabetic gastroparesis. Neurogastroenterol Motil (2013) 2.53
Genetic variation in the CHRNA5 gene affects mRNA levels and is associated with risk for alcohol dependence. Mol Psychiatry (2008) 2.49
Precursor cells of mouse endocrine pancreas coexpress insulin, glucagon and the neuronal proteins tyrosine hydroxylase and neuropeptide Y, but not pancreatic polypeptide. Development (1993) 2.41
Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol (1998) 2.38
Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen. JAMA (1992) 2.32
The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis (1999) 2.27
Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. AIDS Clinical Trials Group Protocol 116B/117 Team and the Virology Committee Resistance Working Group. Ann Intern Med (1995) 2.26
ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother (1998) 2.23
The contribution of L3T4+ T cells to lymphoproliferation and autoantibody production in MRL-lpr/lpr mice. J Exp Med (1988) 2.23
Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J Biol Chem (1994) 2.22
Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumours. Oncogene (2001) 2.22
Transcription from TATA-less promoters: dihydrofolate reductase as a model. Crit Rev Eukaryot Gene Expr (1993) 2.20
Comprehensive processing, display and analysis for in vivo MR spectroscopic imaging. NMR Biomed (2006) 2.19
Spinal anaesthesia with 0.5% isobaric bupivacaine in patients with diabetes mellitus: the influence of CSF composition on sensory and motor block. Eur J Anaesthesiol (2008) 2.15
Genetic susceptibility to systemic lupus erythematosus. Annu Rev Immunol (1998) 2.14
Use of phi(glp-lac) in studies of respiratory regulation of the Escherichia coli anaerobic sn-glycerol-3-phosphate dehydrogenase genes (glpAB). J Bacteriol (1984) 2.13
In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. J Virol (1998) 2.13
Radiolabeled alpha(v)beta3 integrin antagonists: a new class of tracers for tumor targeting. J Nucl Med (1999) 2.11
Ultraviolet light induces binding of antibodies to selected nuclear antigens on cultured human keratinocytes. J Clin Invest (1984) 2.10
Association of cholesteryl ester transfer protein-TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol (2000) 2.10
Parametric manipulation of conflict and response competition using rapid mixed-trial event-related fMRI. Neuroimage (2003) 2.10
Di- and trinucleotide target preferences of somatic mutagenesis in normal and autoreactive B cells. J Immunol (1996) 2.08
The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet (1997) 2.08
Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (1997) 2.08
Nelfinavir, efavirenz, or both after the failure of nucleoside treatment of HIV infection. N Engl J Med (2001) 2.08
Evaluation of TruCount absolute-count tubes for determining CD4 and CD8 cell numbers in human immunodeficiency virus-positive adults. Site Investigators and The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 2.07
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
ADH1B is associated with alcohol dependence and alcohol consumption in populations of European and African ancestry. Mol Psychiatry (2011) 2.05
[Endoscopic cholangiography in biliary tract diseases in HIV+ patients]. Acta Gastroenterol Latinoam (1998) 2.03
Long-term results of monthly inhaled pentamidine as primary prophylaxis of Pneumocystis carinii pneumonia in HIV-infected patients. Am J Med (1993) 2.02
Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. Genes Dev (1996) 2.02
Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett (1991) 2.02
Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J Nucl Med (2001) 2.00
Frequent 3p allele loss and epigenetic inactivation of the RASSF1A tumour suppressor gene from region 3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer (2002) 1.95
Adaptive radiation therapy. Phys Med Biol (1997) 1.94
Analysis of cognitive and psychological deficits in systemic lupus erythematosus patients without overt central nervous system disease. Arthritis Rheum (1996) 1.88
Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. Curr Pharm Des (2006) 1.88
Effect of selected aldehydes on the growth and fermentation of ethanologenic Escherichia coli. Biotechnol Bioeng (1999) 1.87
The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat Med (1996) 1.86
Standardized microtiter assay for determination of syncytium-inducing phenotypes of clinical human immunodeficiency virus type 1 isolates. J Clin Microbiol (1994) 1.85
Prevalence and detection of delirium in elderly emergency department patients. CMAJ (2000) 1.82
Isolation of sequences that span the fragile X and identification of a fragile X-related CpG island. Science (1991) 1.82
Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus. Virology (1998) 1.77
Mechanisms of HIV-associated lymphocyte apoptosis. Blood (2000) 1.75
Fat distribution and metabolic changes are strongly correlated and energy expenditure is increased in the HIV lipodystrophy syndrome. AIDS (2001) 1.74
Enteric bacterial catalysts for fuel ethanol production. Biotechnol Prog (1999) 1.74
The fragile X mental retardation protein is associated with ribosomes. Nat Genet (1996) 1.72
Multisite comparison of CD4 and CD8 T-lymphocyte counting by single- versus multiple-platform methodologies: evaluation of Beckman Coulter flow-count fluorospheres and the tetraONE system. The NIAID DAIDS New Technologies Evaluation Group. Clin Diagn Lab Immunol (2000) 1.71
An off-line strategy for constructing a patient-specific planning target volume in adaptive treatment process for prostate cancer. Int J Radiat Oncol Biol Phys (2000) 1.70
Neurodegeneration and ageing in the HAART era. J Neuroimmune Pharmacol (2008) 1.70
Analysis of full fragile X mutations in fetal tissues and monozygotic twins indicate that abnormal methylation and somatic heterogeneity are established early in development. Am J Med Genet (1992) 1.70
The rationale behind complete mesocolic excision (CME) and a central vascular ligation for colon cancer in open and laparoscopic surgery : proceedings of a consensus conference. Int J Colorectal Dis (2014) 1.69
Treatment of intractable rheumatoid arthritis with total lymphoid irradiation. N Engl J Med (1981) 1.69
Early reduction of immune activation in lymphoid tissue following highly active HIV therapy. AIDS (1998) 1.69
Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA (1998) 1.68
Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team. J Infect Dis (1999) 1.67
Shipment impairs lymphocyte proliferative responses to microbial antigens. Clin Diagn Lab Immunol (2000) 1.67